Controversial FDA Panel Recommends Broader Use of Unproven Peptides Amidst Political Pressure and Scientific Skepticism
admin In a decision poised to significantly reshape the landscape of dietary supplements and compounded medications,...
Biotech, Pharma & Cancer Drug Development
Eli Lilly Delays Retatrutide Filing, Triple-G Drug Poised to Reshape Obesity Market Amidst Cardiovascular Questions
Eli Lilly and Company, a global pharmaceutical leader, has announced a revised timeline for the...
Potential Tariffs on Generic Pharmaceuticals Threaten Widespread Disruption to U.S. Healthcare System
The prospect of significant tariffs, potentially reaching up to 200%, on imported generic pharmaceuticals poses...
GSK Secures Landmark FDA Approval for Jideytro in ROS1-Positive Lung Cancer, Solidifying Its Ambitious Oncology Expansion
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Jideytro, a novel...
Vertex Pharmaceuticals’ $10 Billion Crinetics Acquisition Sparks Investor Debate Over Valuation Amidst Lone Bidder Scenario
Boston, MA – Vertex Pharmaceuticals, a biotechnology giant primarily known for its groundbreaking cystic fibrosis...
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
A genetic medicine developed by Arrowhead Pharmaceuticals, known as plozasiran, has demonstrated compelling success in...
Crystalys Therapeutics Secures $130 Million Series B Funding to Accelerate Global Gout Treatment Program.
Emerging biotech firm Crystalys Therapeutics has announced a substantial $130 million Series B financing round,...
Novartis Navigates Critical Juncture with Q2 Sales Growth Amidst Looming Patent Cliffs and High-Stakes Pipeline Readouts
Novartis AG, the Swiss pharmaceutical giant, experienced a significant surge in its share price on...
Novo Nordisk Files Lawsuit Against Eli Lilly Over "Deceptive" Obesity Drug Advertising Claims
In a significant escalation of the fiercely competitive market for GLP-1 agonist medications, Novo Nordisk...
Agios Pharmaceuticals Faces Setback as Tebapivat Study Fails, Highlighting Persistent Challenges in Sickle Cell Disease Drug Development
The clinical trial failure of Agios Pharmaceuticals’ investigational drug, tebapivat, marks a significant setback for...
